[EN] TREATMENT AND PREVENTION OF HBV DISEASES BY CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACIDES 1 AND 3<br/>[FR] TRAITEMENT ET PRÉVENTION DE MALADIES DU VHB PAR DES MOLÉCULES ANALOGUES DE CYCLOSPORINE MODIFIÉES AU NIVEAU DES ACIDES AMINÉS 1 ET 3
申请人:CONTRAVIR PHARMACEUTICALS INC
公开号:WO2018106928A1
公开(公告)日:2018-06-14
The present application relates to a method of treating and/or preventing a hepatitis B virus (HBV) disease through inhibiting the interaction of CypA with HBV X protein (HBx) and/or Hepatitis B surface antigen (HBsAg), comprising administering to a subject in need thereof a compound of Formula L.
Practical Synthesis of Chiral Allylboronates by Asymmetric 1,1‐Difunctionalization of Terminal Alkenes
作者:Caocao Sun、Yuqiang Li、Guoyin Yin
DOI:10.1002/anie.202209076
日期:2022.9.12
A highly 1,1-regio- and enantioselective alkenylboration of undirected and unactivated alkenes has been developed, which allows chiral allylboronates to be efficiently synthesized from readily available terminal alkenes, alkenyl bromides and B2pin2. This method is distinguished by its use of an inexpensive chiral catalyst, readily available starting materials, mild and convenient reaction conditions
已经开发了一种高度 1,1-区域和对映选择性的无向和未活化烯烃的烯基硼化反应,它允许从容易获得的末端烯烃、烯基溴化物和 B 2 pin 2有效地合成手性烯丙基硼酸酯。该方法的特点是使用廉价的手性催化剂、容易获得的起始材料、温和方便的反应条件、可扩展性和实用性。
Nickel-Catalyzed Regio- and Enantioselective Borylative Coupling of Terminal Alkenes with Alkyl Halides Enabled by an Anionic Bisoxazoline Ligand
Chiral boronic esters are a class of versatile building blocks. We describe herein an asymmetric nickel-catalyzed borylative coupling of terminal alkenes with nonactivated alkyl halides. The success of this asymmetric reaction is ascribed to the application of a chiral anionic bisoxazoline ligand. This study provides a three-component strategy to access α- and β-stereogenic boronic esters from easily
CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3
申请人:ContraVir Pharmaceuticals, Inc.
公开号:EP3461835A1
公开(公告)日:2019-04-03
Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula (I). The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.